Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

Fineline Cube Jun 29, 2026
Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026
Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Eli Lilly’s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use

Fineline Cube Jun 29, 2026
Company Drug

J&J’s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line

Fineline Cube Jun 29, 2026
Company Deals

Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure

Fineline Cube Nov 9, 2022

US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA),...

Company Deals

Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure

Fineline Cube Nov 9, 2022

US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA),...

Company Drug

MicuRx Pharmaceuticals Doses First Patient in China for MRX-8 Trial

Fineline Cube Nov 9, 2022

Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the first patient dosing in...

Company Drug

Zhifei Bio Initiates Global Study for Omicron-Delta COVID-19 Vaccine in Uzbekistan

Fineline Cube Nov 9, 2022

China-based Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd has announced the initiation of a global clinical study...

Company Deals

Mainline Biosciences Raises RMB 100M in Series A Financing for Peptide Drugs

Fineline Cube Nov 9, 2022

Mainline Biosciences, a polypeptide drug developer based in Zhongshan, has reportedly raised close to RMB...

Company Deals

Jiangsu Trausim Raises RMB 100M in Series A Financing for Dental Implants

Fineline Cube Nov 9, 2022

China-based Jiangsu Trausim Medical Instrument Co., Ltd, a wholly-owned subsidiary of Fulong Holdings and focused...

Company Drug

Cyramza Prescribed in China for Advanced Gastric Cancer

Fineline Cube Nov 9, 2022

Cyramza (ramucirumab) was first prescribed on November 6, 2022, at the Zhongshan Hospital in Shanghai...

Company Deals

Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization

Fineline Cube Nov 9, 2022

German pharmaceutical giant Merck KGaA (ETR: MRK) has announced a collaboration with Biotheus, a China-based...

Company Drug

Merck’s Keytruda Receives 10th Indication Approval in China for TNBC

Fineline Cube Nov 9, 2022

US-based Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab) has...

Company Deals

Takeda Partners with CCCMHPIE to Boost Rare Disease Drug Access in China

Fineline Cube Nov 8, 2022

The 5th China International Import Expo (CIIE) saw Japan-based Takeda Pharmaceutical Co., Ltd’s China unit...

Company Deals

Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies

Fineline Cube Nov 8, 2022

Xellsmart, a stem-cell startup based in Suzhou, has reportedly raised over RMB 200 million (USD...

Company

Novo Nordisk Reports 16% YOY Growth in Q3, Raises Full-Year Guidance

Fineline Cube Nov 8, 2022

Denmark-based biopharma Novo Nordisk A/S (NYSE: NVO) has released its Q3 2022 earnings report. The...

Company Deals

Novo Nordisk Partners with Shanghai Pharma for Smart Logistics at CIIE

Fineline Cube Nov 8, 2022

Novo Nordisk (NYSE: NVO) has announced a strategic partnership with China’s Shanghai Pharmaceuticals (HKG: 2607,...

Company Deals

SIMR Biotechnology Raises RMB 150M in Series C1 Financing Round

Fineline Cube Nov 8, 2022

China’s Shanghai SIMR Biotechnology Co., Ltd has reportedly raised RMB 150 million (USD 20.7 million)...

Company Deals Digital

PingAn Good Doctor Partners with Roche and OrigiMed at CIIE

Fineline Cube Nov 8, 2022

The 5th China International Import Expo (CIIE) saw China-based Ping An Healthcare and Technology Co.,...

Company Deals Digital

Organon Partners with Alibaba Health to Enhance Chronic Disease Management

Fineline Cube Nov 8, 2022

Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that...

Company Drug

Qilu Pharma’s QL1706 Shows Promise in Phase II Cervical Cancer Study

Fineline Cube Nov 8, 2022

China-based Qilu Pharmaceutical has published the latest results from a Phase II clinical study for...

Company Deals

Organon Sponsors Retail Pharmacy Health Center at CIIE

Fineline Cube Nov 8, 2022

The 5th China International Import Expo (CIIE) saw Organon & Co. (NYSE: OGN), a firm...

Company Deals

Sanofi Partners with China Resources Sanjiu at CIIE for Consumer Healthcare

Fineline Cube Nov 8, 2022

The 5th China International Import Expo (CIIE) saw Sanofi’s consumer healthcare unit announce a partnership...

Company Deals

Sumitomo Dainippon Partners with Profex to Promote Antipsychotics in China

Fineline Cube Nov 8, 2022

Japan-based Sumitomo Dainippon Pharma Co., Ltd has announced a partnership with Profex, a trade company...

Posts pagination

1 … 626 627 628 … 688

Recent updates

  • Eli Lilly’s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use
  • Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax
  • J&J’s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line
  • China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs
  • NHSA Advances Record 674 Drugs in 2026 Insurance Catalog Review with 92% Preliminary Pass Rate
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Eli Lilly’s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use

Company Deals

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

Company Drug

J&J’s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line

Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.